References in periodicals archive ?
CD3- and CD28-dependent induction of PDE7 required for T cell activation.
M2 EQUITYBITES-February 23, 2011-Omeros expands exclusive license to PDE7 inhibitors from Daiichi Sankyo(C)2011 M2 COMMUNICATIONS http://www.
Omeros' PDE7 programme was founded on the company's discovery of a previously unknown link between PDE7 and any movement disorder, such as Parkinson's disease.
The company said that it believes that it also is the first to link PDE7 to any addiction or compulsive behaviour, and is now advancing PDE7 inhibitors for the treatment of these as well as movement disorders.
From the advanced Daiichi compounds, Omeros has reportedly already selected a clinical candidate, and expects that addiction will provide it with a faster and less expensive development pathway for its PDE7 programme.
7 PDE6 38 157 780 PDE7 21,000 <30,000 >100,000 PDE8 29,800 >30,000 >100,000 PDE9 2,610 580 >100,000 PDE10 9,800 3,000 >100,000 PDE11 2,730 162 37 * [IC.
TABLE 1 Selectivity ratios of PDE inhibitors Sildenafil Vardenafil Tadalafil PDE1 80 257 >10,000 PDE2 >7500 >10,000 >10,000 PDE3 4400 3600 >10,000 PDE4 1800 5700 >10,000 PDE5 1 1 1 PDE6 10 224 780 PDE7 5160 No data >10,000 PDE8 >10,000 No data >10,000 PDE9 2796 No data >10,000 PDE10 1123 447 >10,000 PDE11 346 203 5.
Medical browser ?
Full browser ?
- PDE4 inhibitor